Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Selina Koch says Arrowhead's healthy-volunteer data showed up to 73% tau knockdown, a first for siRNA in people. But Biogen's intrathecal antisense showed more knockdown at higher doses without matching efficacy; the lowest dose worked best, raising whether excess tau knockdown is harmful; patient data are needed.

Related Insights

Biogen's anti-tau ASO trial missed its primary endpoint because the lowest dose performed best—a biologically counterintuitive 'inverse dose-response.' This result challenges the drug's fundamental mechanism of action, as more drug should theoretically lead to better effect, creating a high bar for convincing regulators and investors of its viability.

In multiple instances where siRNA and ASO (antisense) therapies have been developed for the same indication, the siRNA drug has emerged with a superior overall profile across efficacy, safety, and dosing convenience. This pattern suggests siRNA is solidifying its position as the more advantageous modality.

Biogen is proceeding to a Phase 3 trial with its tau-targeting Alzheimer's drug even though the mid-stage study technically failed its primary endpoint. The lowest dose performed best, contrary to expectations. This signals a strategy of pushing forward with mechanistically promising but complex drugs by positively framing ambiguous data.

Biogen is proceeding with its anti-tau therapy Duranderson, even though it missed its primary endpoint. The rationale is that the observed slowing of cognitive decline on secondary measures (26-50%) is comparable, or even slightly better than, the results of already-approved anti-amyloid antibodies. This strategy shows how a technically 'failed' trial can find a path forward by meeting the efficacy bar set by existing treatments.

Voyager CEO Al Sandrock suggests the 30% average efficacy of new Alzheimer's drugs isn't uniform. Instead, some patients may see a complete halt in progression while others see no benefit. He argues the next critical step is predicting these responders, which will determine whether future therapies like anti-tau agents should be added on or used as a replacement.

Phase 2 data for Biogen's Diranersin showed the lowest dose had the best cognitive results but also the least effect on the tau protein it's designed to target. This confounding result creates significant uncertainty for the company as it decides whether to fund a costly Phase 3 trial.

After several tau-targeting antibodies failed, including J&J's pazdenimab, confidence in blocking extracellular tau is waning. The field's new hope is Biogen’s Biv80, an antisense drug that prevents tau protein production at the mRNA level, a mechanism that has shown potential to reverse pathology in early data.

Biogen's Phase 2 data for BIV80 is pivotal because its antisense mechanism targets Tau at the mRNA level, reducing all forms of the protein. This "turns off the faucet" approach provides a broad, definitive test of whether targeting Tau itself is a viable strategy for Alzheimer's, bypassing the complexity of its various forms.

Arrowhead's demonstration of over 80% tau knockdown in CSF signals that transferrin-mediated delivery is expanding beyond enzymes and antibodies into siRNA conjugates. Much like GalNAc revolutionized liver targeting, transferrin technology is maturing across multiple competitors to overcome blood-brain barrier penetration challenges.

Though Biogen's Alzheimer's drug Dira Nursen technically failed its Phase 2 trial, experts view the results as encouraging for the tau protein as a target. The trial's inverted dose-response and mixed results are attributed to the ASO delivery platform's known tolerability issues, suggesting better modalities could still succeed.